SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL - Research portal of Justus Liebig University Giessen:

Meeting Abstract

SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL

Authors list: Denton, Christopher; Khanna, Dinesh; Jahreis, Angelika; van Laar, Jacob M.; Cheng, Sabrina; Spotswood, Helen; Pope, Janet E.; Allanore, Yannick; Mueller-Ladner, Ulf; Siegel, Jeffrey; Furst, Daniel E.

Publication year: 2016

Pages: 47-48

Journal: Rheumatology

Volume number: 55

ISSN: 1462-0324

eISSN: 1462-0332

Conference: Annual Meeting of the British-Society-for-Rheumatology, British-Health-Professionals-in-Rheumatology and the British-Society-for-Paediatric-and-Adolescent-Rheumatology (Rheumatology)

Publisher: Oxford University Press

Citation Styles

Harvard Citation style: Denton, C., Khanna, D., Jahreis, A., van Laar, J., Cheng, S., Spotswood, H., et al. (2016) SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL, Rheumatology, 55, pp. 47-48

APA Citation style: Denton, C., Khanna, D., Jahreis, A., van Laar, J., Cheng, S., Spotswood, H., Pope, J., Allanore, Y., Mueller-Ladner, U., Siegel, J., & Furst, D. (2016). SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL. Rheumatology. 55, 47-48.